Pfizer, Inc. (NYSE:PFE) Position Reduced by Alpha Cubed Investments LLC

Alpha Cubed Investments LLC trimmed its stake in Pfizer, Inc. (NYSE:PFE) by 26.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,044 shares of the biopharmaceutical company’s stock after selling 10,942 shares during the quarter. Alpha Cubed Investments LLC’s holdings in Pfizer were worth $1,043,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Northstar Group Inc. lifted its position in shares of Pfizer by 0.4% in the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 35 shares in the last quarter. Meridian Wealth Management LLC lifted its position in shares of Pfizer by 0.5% in the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after purchasing an additional 57 shares in the last quarter. Stone House Investment Management LLC lifted its position in shares of Pfizer by 0.9% in the first quarter. Stone House Investment Management LLC now owns 7,164 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 66 shares in the last quarter. Naples Global Advisors LLC lifted its position in shares of Pfizer by 0.3% in the first quarter. Naples Global Advisors LLC now owns 24,552 shares of the biopharmaceutical company’s stock worth $840,000 after purchasing an additional 79 shares in the last quarter. Finally, Asset Planning Services Ltd. lifted its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares in the last quarter. 69.00% of the stock is owned by institutional investors and hedge funds.

Shares of Pfizer, Inc. (NYSE PFE) opened at 35.74 on Friday. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $36.78. The firm has a market cap of $212.56 billion, a P/E ratio of 26.14 and a beta of 1.00. The stock has a 50 day moving average of $35.72 and a 200 day moving average of $33.87.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. The firm had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.64 EPS. Equities analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.58%. The ex-dividend date is Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is currently 94.12%.

WARNING: “Pfizer, Inc. (NYSE:PFE) Position Reduced by Alpha Cubed Investments LLC” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2017/10/27/alpha-cubed-investments-llc-sells-10942-shares-of-pfizer-inc-pfe.html.

In other news, insider Sally Susman sold 38,230 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at approximately $5,097,715. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. Over the last three months, insiders have sold 464,521 shares of company stock worth $15,813,961. 0.06% of the stock is currently owned by insiders.

Several equities analysts recently weighed in on the stock. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 10th. BidaskClub lowered shares of Pfizer from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 13th. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Friday, July 14th. Jefferies Group LLC reaffirmed a “hold” rating and set a $35.00 price objective (up previously from $34.00) on shares of Pfizer in a research report on Friday, July 14th. Finally, Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, July 17th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $38.32.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply